Teresa A Zimmers

List of Publications by Year
in descending order

133	7,469	66234	54797
papers	citations	42 h-index	84 g-index

139	139	139	10103
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1418-1425.	2.9	19
2	Activin A Causes Muscle Atrophy through MEF2C-Dependent Impaired Myogenesis. Cells, 2022, 11, 1119.	1.8	6
3	Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2146-2161.	2.9	31
4	STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Life Science Alliance, 2022, 5, e202201460.	1.3	19
5	Changes in Serum Myostatin Levels in Alcoholic Hepatitis Correlate with Improvement in MELD. Digestive Diseases and Sciences, 2021, 66, 3062-3073.	1.1	2
6	Combined inhibition of Refâ€1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour coâ€culture models. Journal of Cellular and Molecular Medicine, 2021, 25, 784-800.	1.6	9
7	Agingâ€associated skeletal muscle defects in HER2/Neu transgenic mammary tumour model. JCSM Rapid Communications, 2021, 4, 24-39.	0.6	5
8	Editorial: Highlights from the 2020 virtual cancer cachexia conference. Current Opinion in Supportive and Palliative Care, 2021, 15, 48-49.	0.5	0
9	What's New in Shock, February 2021?. Shock, 2021, 55, 143-146.	1.0	0
10	Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. Cancers, 2021, 13, 1975.	1.7	9
11	Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. Journal of Experimental Medicine, 2021, 218, .	4.2	89
12	Abstract 133: Skeletal muscle transcriptome profiling of human pancreatic cancer cachexia: single largest study in cachexia. , 2021, , .		0
13	Abstract 2657: Sex differences in pancreatic cancer cachexia manifestations and mechanisms in mice and humans: Role of activin. Cancer Research, 2021, 81, 2657-2657.	0.4	1
14	Abstract 969: PKC-theta modulates myosteatosis, muscle function, atrophy, and survival in murine pancreatic ductal adenocarcinoma. , 2021, , .		0
15	Hormonally Regulated Myogenic miR-486 Influences Sex-specific Differences in Cancer-induced Skeletal Muscle Defects. Endocrinology, 2021, 162, .	1.4	4
16	Epidermal PPARÎ³ Is a Key Homeostatic Regulator of Cutaneous Inflammation and Barrier Function in Mouse Skin. International Journal of Molecular Sciences, 2021, 22, 8634.	1.8	7
17	Nutrition challenges of cancer cachexia. Journal of Parenteral and Enteral Nutrition, 2021, 45, 16-25.	1.3	12
18	Case presentation and panel discussion: Nutrition issues in cancer. Journal of Parenteral and Enteral Nutrition, 2021, 45, 41-46.	1.3	0

#	Article	IF	Citations
19	Sex Differences in Cancer Cachexia. Current Osteoporosis Reports, 2020, 18, 646-654.	1.5	49
20	ACVR2B antagonism as a countermeasure to multiâ€organ perturbations in metastatic colorectal cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1779-1798.	2.9	26
21	Pathological Responses of Cardiac Mitochondria to Burn Trauma. International Journal of Molecular Sciences, 2020, 21, 6655.	1.8	7
22	Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform. Cancers, 2020, 12, 3787.	1.7	27
23	In Vitro, In Vivo, and In Silico Methods for Assessment of Muscle Size and Muscle Growth Regulation. Shock, 2020, 53, 605-615.	1.0	8
24	The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 1605.	1.7	12
25	miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2. Molecular Cancer Research, 2020, 18, 311-323.	1.5	27
26	Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia. JCI Insight, 2020, 5, .	2.3	20
27	Abstract 2644: Oncostatin M in pancreatic cancer tumor microenvironment. , 2020, , .		0
28	RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice. Journal of Bone and Mineral Research, 2020, 37, 381-396.	3.1	13
29	The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1083-1101.	2.9	46
30	Age- and sex-dependent role of osteocytic pannexin1 on bone and muscle mass and strength. Scientific Reports, 2019, 9, 13903.	1.6	12
31	Multimodal Action of Mas Activation for Systemic Cancer Cachexia Therapy. Cancer Research, 2019, 79, 699-700.	0.4	3
32	Voluntary Wheel Running Has Beneficial Effects in a Rat Model of CKD-Mineral Bone Disorder (CKD-MBD). Journal of the American Society of Nephrology: JASN, 2019, 30, 1898-1909.	3.0	9
33	What's New in Shock, July 2019?. Shock, 2019, 52, 1-4.	1.0	0
34	Pancreas Cancer-Associated Weight Loss. Oncologist, 2019, 24, 691-701.	1.9	99
35	Resveratrol Improves Recovery and Survival of Diet-Induced Obese Mice Undergoing Extended Major (80%) Hepatectomy. Digestive Diseases and Sciences, 2019, 64, 93-101.	1.1	5
36	Modelling survival. ELife, 2019, 8, .	2.8	1

#	Article	IF	Citations
37	Association Between IL6R Polymorphisms and Cachexia Phenotype in Patients with Pancreatic Ductal Adenocarcinoma. Proceedings of IMPRS, 2019, 2, .	0.0	0
38	Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice. Surgery, 2018, 163, 1264-1271.	1.0	1
39	Circulating monocyte chemoattractant proteinâ€1 (MCPâ€1) is associated with cachexia in treatmentâ€naÃ¯ve pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 358-368.	2.9	73
40	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut, 2018, 67, 320-332.	6.1	381
41	An Assessment of the Academic Impact of Shock Society Members. Shock, 2018, 49, 508-513.	1.0	1
42	Three cachexia phenotypes and the impact of fatâ€only loss on survival in FOLFIRINOX therapy for pancreatic cancer. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 673-684.	2.9	98
43	Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 685-700.	2.9	74
44	GDF11 induces kidney fibrosis, renal cell epithelial-to-mesenchymal transition, and kidney dysfunction and failure. Surgery, 2018, 164, 262-273.	1.0	18
45	Sarcopenia is a Significant Predictor of Mortality After Abdominal Aortic Aneurysm Repair. JCSM Clinical Reports, 2018, 3, 1-12.	0.5	8
46	Deletion of Tumorâ€derived ILâ€6 Maintains Muscle Mass and Attenuates Lipolysis with Evidence for soluble ILâ€6RÎ± as a Driver of Pancreatic Cancer Cachexia. FASEB Journal, 2018, 32, 659.8.	0.2	0
47	Sarcopenia is a Significant Predictor of Mortality After Abdominal Aortic Aneurysm Repair. JCSM Clinical Reports, 2018, 3, .	0.5	5
48	The Role of PhD Faculty in Advancing Research in Departments of Surgery. Annals of Surgery, 2017, 265, 111-115.	2.1	18
49	Endangered academia: preserving the pediatric surgeon scientist. Journal of Pediatric Surgery, 2017, 52, 1079-1083.	0.8	10
50	Bone Pain and Muscle Weakness in Cancer Patients. Current Osteoporosis Reports, 2017, 15, 76-87.	1.5	23
51	Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases. Endocrinology, 2017, 158, 664-677.	1.4	66
52	Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2747-2758.	1.9	19
53	Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting. Basic Research in Cardiology, 2017, 112, 48.	2.5	78
54	Epidermal growth factor receptor restoration rescues the fatty liver regeneration in mice. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E440-E449.	1.8	20

#	Article	IF	Citations
55	Impact of Integrated Vascular Residencies on Academic Productivity within Vascular Surgery Divisions. Annals of Vascular Surgery, 2017, 39, 242-249.	0.4	1
56	Vitamin D and VDR in cancer cachexia and muscle regeneration. Oncotarget, 2017, 8, 21778-21793.	0.8	37
57	Abstract P6-15-03: Dual targeting of mammary tumors and tumor-associated functional limitations through inhibition of NF-kB. , 2017, , .		0
58	Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget, 2016, 7, 43442-43460.	0.8	145
59	Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. Frontiers in Physiology, 2016, 7, 472.	1.3	138
60	The impact of members of the Society of University Surgeons onÂthe scholarship of American surgery. Surgery, 2016, 160, 47-53.	1.0	6
61	Do Plastic Surgery Programs with Integrated Residencies or Subspecialty Fellowships Have Increased Academic Productivity?. Plastic and Reconstructive Surgery - Global Open, 2016, 4, e614.	0.3	8
62	The positive association of Association for Academic Surgery membership with academic productivity. Journal of Surgical Research, 2016, 205, 163-168.	0.8	7
63	Impact of clinical fellowships on academic productivity in departments of surgery. Surgery, 2016, 160, 1440-1446.	1.0	6
64	Hypermetabolism and hypercatabolism of skeletal muscle accompany mitochondrial stress following severe burn trauma. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E436-E448.	1.8	36
65	The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia. Journal of Visualized Experiments, 2016, , .	0.2	75
66	Is there an impending loss of academically productive trauma surgical faculty? An analysis of 4,015 faculty. Journal of Trauma and Acute Care Surgery, 2016, 81, 244-253.	1.1	7
67	Understanding the Barriers to Hiring and Promoting Women in Surgical Subspecialties. Journal of the American College of Surgeons, 2016, 223, 387-398e2.	0.2	66
68	STAT3 in the systemic inflammation of cancer cachexia. Seminars in Cell and Developmental Biology, 2016, 54, 28-41.	2.3	171
69	Protecting Ideas: Ethical and Legal Considerations When a Grantâ€™s Principal Investigator Changes. Science and Engineering Ethics, 2016, 22, 1051-1061.	1.7	1
70	Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Frontiers in Physiology, 2016, 7, 679.	1.3	44
71	The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia. Frontiers in Physiology, 2016, 7, 682.	1.3	20
72	Abstract B35: Molecular and phenotypic profiling of pancreatic cancer cachexia in novel murine models and patients. , 2016, , .		0

#	Article	IF	Citations
73	Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer. , 2015, 3, .		4
74	Have the New Training Pathways Enhanced Academic Productivity in Plastic Surgery?. Plastic and Reconstructive Surgery, 2015, 136, 62.	0.7	2
75	Current management ofÂgastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy. Surgery, 2015, 158, 1149-1164.	1.0	52
76	Determining the Drivers of Academic Success in Surgery: An Analysis of 3,850 Faculty. Journal of the American College of Surgeons, 2015, 221, S123.	0.2	1
77	What are the barriers to hiring and promoting women in surgery?. Journal of the American College of Surgeons, 2015, 221, e76-e77.	0.2	0
78	Determining the Drivers of Academic Success in Surgery: An Analysis of 3,850 Faculty. PLoS ONE, 2015, 10, e0131678.	1.1	48
79	An invitation to the 2nd Cancer Cachexia Conference, MontrÃ©al, Canada. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 181-181.	2.9	0
80	Electronic Medical Record: A Balancing Act of Patient Safety Privacy Health Care Delivery. American Journal of the Medical Sciences, 2014, 348, 238-243.	0.4	18
81	Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18940-18945.	3.3	95
82	Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation. Blood, 2013, 122, 598-607.	0.6	121
83	Abstract A6: The ES-2 ovarian cancer causes muscle wasting in vitro and in vivo: A novel experimental model of cancer cachexia. , 2013, , .		0
84	JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E410-E421.	1.8	318
85	Hedgehog Signaling Regulates Bladder Cancer Growth and Tumorigenicity. Cancer Research, 2012, 72, 4449-4458.	0.4	43
86	BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood, 2012, 119, 6162-6171.	0.6	206
87	Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 199-211.	2.9	58
88	The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival. Cancer, 2012, 118, 4495-4501.	2.0	42
89	Increase in Muscle Mitochondrial Biogenesis Does Not Prevent Muscle Loss but Increased Tumor Size in a Mouse Model of Acute Cancer-Induced Cachexia. PLoS ONE, 2012, 7, e33426.	1.1	38
90	Mitochondrial Fission Induces Glycolytic Reprogramming in Cancer-Associated Myofibroblasts, Driving Stromal Lactate Production, and Early Tumor Growth. Oncotarget, 2012, 3, 798-810.	0.8	112

#	Article	IF	Citations
91	The Influence of Latino Ethnicity on the Outcomes for Patients with Non-small Cell Lung Cancer: An Analysis of the Survival, Epidemiology, and End Results (SEER) Database. International Journal of Radiation Oncology Biology Physics, 2011, 81, S597.	0.4	1
92	Obesity and Weight Loss at Presentation of Lung Cancer are Associated with Opposite Effects on Survival. Journal of Surgical Research, 2011, 170, e75-e83.	0.8	85
93	STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia. PLoS ONE, 2011, 6, e22538.	1.1	284
94	Is Surgical Resection Superior to Transplantation in the Treatment of Hepatocellular Carcinoma?. Annals of Surgery, 2011, 254, 527-538.	2.1	96
95	Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptorâ€“deficient mouse. Metabolism: Clinical and Experimental, 2011, 60, 1610-1619.	1.5	9
96	Regulation of Muscle Mass by Follistatin and Activins. Endocrine Reviews, 2010, 31, 776-776.	8.9	0
97	Perspective: PhD Scientists Completing Medical School in Two Years: Looking at the Miami PhD-to-MD Program Alumni Twenty Years Later. Academic Medicine, 2010, 85, 687-691.	0.8	16
98	Loss of GDF-15 abolishes Sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. Journal of Cancer Research and Clinical Oncology, 2010, 136, 571-576.	1.2	36
99	Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer. Cancer Biology and Therapy, 2010, 10, 108-109.	1.5	0
100	Regulation of Muscle Mass by Follistatin and Activins. Molecular Endocrinology, 2010, 24, 1998-2008.	3.7	234
101	Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut, 2010, 59, 186-196.	6.1	84
102	Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochemical and Biophysical Research Communications, 2010, 391, 1548-1554.	1.0	204
103	Abstract 5101: Acute inhibition of myostatin-family proteins preserves muscle in cancer cachexia. , 2010, , .		0
104	A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Research and Treatment, 2009, 117, 631-641.	1.1	17
105	Body Surface Area Prediction in Normal, Hypermuscular, and Obese Mice. Journal of Surgical Research, 2009, 153, 326-331.	0.8	79
106	Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis. Journal of Cancer Research and Clinical Oncology, 2008, 134, 753-759.	1.2	43
107	SUS/AAS abstracts: what is the scientific impact?. Surgery, 2008, 144, 322-331.	1.0	18
108	Scientific Impact of Women in Academic Surgery. Journal of Surgical Research, 2008, 148, 13-16.	0.8	42

#	Article	IF	Citations
109	Ethical Implications of Modifying Lethal Injection Protocols. PLoS Medicine, 2008, 5, e126.	3.9	5
110	Physician participation in lethal injection executions. Current Opinion in Anaesthesiology, 2007, 20, 147-151.	0.9	14
111	How Important Is the Contribution of Surgical Specialties to a Medical Schoolâ€™s NIH Funding?. Journal of Surgical Research, 2007, 141, 16-21.	0.8	14
112	Can lethal injection for execution really be â€œfixedâ€?. Lancet, The, 2007, 369, 352-353.	6.3	4
113	NAG-1/GDF-15: No Evidence for an Inhibitory Role in Colon Cancer?. Gastroenterology, 2007, 132, 1204-1205.	0.6	3
114	Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology, 2007, 46, 802-812.	3.6	76
115	GDF-15 mediates the anti-tumorigenic effects of NSAIDs in intestinal cancers. Journal of the American College of Surgeons, 2007, 205, S37.	0.2	0
116	Lethal Injection for Execution: Chemical Asphyxiation?. PLoS Medicine, 2007, 4, e156.	3.9	25
117	Growth Differentiation Factor-15: Induction in Liver Injury Through p53 and Tumor Necrosis Factor-Independent Mechanisms1. Journal of Surgical Research, 2006, 130, 45-51.	0.8	60
118	Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology, 2006, 43, 474-484.	3.6	151
119	Inadequate anaesthesia in lethal injection for execution. Lancet, The, 2005, 365, 1412-1414.	6.3	77
120	Inadequate anaesthesia in lethal injection for execution â€“ Authors' reply. Lancet, The, 2005, 366, 1074-1076.	6.3	5
121	Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock, 2005, 23, 543-8.	1.0	142
122	Two Third-Year Medical Studentâ€“Level Laboratory Shock Exercises without Large Animals. Surgical Infections, 2004, 5, 343-348.	0.7	9
123	Massive liver growth in mice induced by systemic interleukin 6 administration. Hepatology, 2003, 38, 326-334.	3.6	120
124	Resolving the role of IL-6 in liver regeneration. Hepatology, 2003, 38, 1590-1591.	3.6	28
125	Liver regeneration. Journal of the American College of Surgeons, 2003, 197, 634-659.	0.2	236
126	Suppressor of Cytokine Signaling-3 (SOCS-3), a Potential Mediator of Interleukin-6-dependent Insulin Resistance in Hepatocytes. Journal of Biological Chemistry, 2003, 278, 13740-13746.	1.6	521

#	Article	IF	Citations
127	Chronic Exposure to Interleukin-6 Causes Hepatic Insulin Resistance in Mice. Diabetes, 2003, 52, 2784-2789.	0.3	443
128	Induction of Cachexia in Mice by Systemically Administered Myostatin. Science, 2002, 296, 1486-1488.	6.0	829
129	Massive liver growth induced by interleukin-6 overexpression in mice. Journal of Hepatology, 2002, 36, 81.	1.8	0
130	Transient Down-regulation of Inhibin-Î²C Expression Following Partial Hepatectomy. Biochemical and Biophysical Research Communications, 1997, 235, 553-556.	1.0	40
131	The Expression and Role of Human Erythropoietin Receptor in Erythroid and Nonerythroid Cells. Annals of the New York Academy of Sciences, 1994, 718, 232-244.	1.8	3
132	Assessment of Cachexia Markers in the TCGA-LIHC Cohort of Patients with Hepatocellular Carcinoma. Proceedings of IMPRS, 0, 3, .	0.0	0
133	Characterizing Muscle Phenotype and Prognosis in Patients with Multiple Myeloma. Proceedings of IMPRS, 0, 3, .	0.0	0